Drug Topics May 13, 2022
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
As a society and a healthcare system, we have waited a long time for advancements in care that biologic medicines offer. These drugs, made from living cells, have dramatically changed how many serious conditions – such as certain cancers, diabetes, rheumatoid arthritis and others – are treated.
For example, whereas older treatments for autoimmune conditions may reduce symptoms, biologics work differently. They are designed to modulate the immune responses that lead to conditions like rheumatoid or psoriatic arthritis in joints, atopic dermatitis in the skin, ulcerative colitis in the intestines, and many more.
These immune responses trigger inflammation in certain organ...
Today's Sponsors
Today's Sponsor